HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
तुलना करने के लिए मीट्रिक्स | HOOK | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधHOOKपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.3x | −0.6x | −0.5x | |
PEG अनुपात | 0.01 | −0.01 | 0.00 | |
क़ीमत/बुक | 0.6x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.0x | 18.2x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 196.1% | 316.7% | 48.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.2% | 9.2% | अनलॉक करें |